The Advanced Integrative Molecular Probe Collaboration's mission is to develop new imaging agents in a multidisciplinary approach to monitor, understand and cure disease at an early stage.

The Luo lab studies hypoxia stress in human cancers with a focus on epigenetic and metabolic alterations. 

Our laboratory is interested in studying the intersection between lung cancer and immunology. We are currently focused on co-opting innate immune signaling pathways and tumor-associated T cell populations to target diverse subsets of lung cancer.

Drapkin Lab investigates the molecular drivers of oncogenesis, metastasis, and chemoresistance in small cell lung cancer (SCLC) to discover new therapeutic targets. 

research lab at UT Southwestern for Yun "Claudia" Wei, Ph.D.

The goal of the Choi Lab is to develop novel immunotherapies. To accomplish this, we first utilize high-dimensional approaches on human disease samples. This approach identifies targetable disease-promoting molecular defects in immune cells. Then, we utilize engineering approaches ot reverse the molecular changes.

Leveraging cutting-edge genetic and chemical screens to uncover novel and enhanced therapeutics for cancer treatment.

The Neuro-Oncology Translational Research Laboratory studies primary brain tumors from pure basic science through the continuum to clinical trials. 

Dr. Zhu has investigated disease mechanisms and attempted to develop novel therapeutic strategies for tumor suppressor gene (TSG), syndrome-associated tumors in the nervous system, and neuropsychiatric disorders.

Our laboratory’s focus is to understand the intrinsic roles of lysosomes and their regulatory functions in cellular and organismal homeostasis, with the ultimate goal of identifying novel therapeutic targets for a wide range of disease conditions.